FDA Removes REMS Requirement for BLINCYTO®


A Risk Evaluation and Mitigation Strategy (REMS) is a drug safety program that the U.S. Food and Drug Administration (FDA) can require for certain medications with serious safety concerns to help ensure the benefits of the medication outweigh its risks.  The BLINCYTO® REMS was first approved by the FDA in 2014 and last updated in […]

Read More